ArticleIn vivo (Athens, Greece)
Robot-assisted Sacrocolpopexy Efficacy and Safety for Lower Urinary Tract Dysfunction Associated With Pelvic Organ Prolapse.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimPelvic organ prolapse (POP) is a condition in which the bladder, uterus, or rectum prolapses from the vagina. Assessing the presence or absence of POP is important when examining for lower urinary tract dysfunction (LUTD) in women. However, reports on changes in LUTD before and after robot-assisted sacrocolpopexy (RSC) are scarce. This study aimed to explore the progression of LUTD after RSC for POP. PATIENTS AND
methodsPatients with POP who underwent RSC at the Department of Urology, Nara Medical University, between July 1, 2021, and September 30, 2024, were enrolled. Patient background, perioperative uroflowmetry results, treatment efficacy, and safety were retrospectively evaluated.
resultsIn total, 23 patients were included in the study, with a median age of 74.0 years at the time of surgery. The total international prostate symptom score and quality of life scores were significantly lower at 4 weeks after surgery than at baseline and continued to decrease at 12 and 24 weeks. The maximum flow rate was significantly higher at 4 weeks after surgery than at baseline and continued to increase at 12 and 24 weeks. The post-void residual urine volume was significantly lower at 4 weeks after surgery than at baseline and continued to decrease at 12 and 24 weeks. Postoperative complications included urinary incontinence (grade II and IIIb) in two patients and intestinal obstruction (grade IIIb) in one patient. Two cases of stage II recurrence were identified, but after consultation with the patients, no reoperation was performed.
conclusionRSC appears to be a clinically useful option for pelvic organ prolapse with concomitant lower urinary tract dysfunction, providing meaningful postoperative functional improvement with an acceptable safety profile. Larger comparative studies with longer follow up are needed to confirm durability and better define patient selection and complication prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.